Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
18 August 2021 | Story ANDRÉ DAMONS | Photo ANDRÉ DAMONS
Dr Osayande Evbuomwan, a Senior Lecturer and Medical Specialist in the Department of Nuclear Medicine, always wanted to specialise in an area of medicine that was novel, innovative, intriguing and involved a lot of opportunities for groundbreaking research

Dr Osayande Evbuomwan, Senior Lecturer and Medical Specialist in the Department of Nuclear Medicine, Faculty of Health Sciences, at the University of the Free State (UFS) always wanted to specialize in an area of medicine that was novel, innovative, intriguing and involved many opportunities for groundbreaking research.

This passionate medical man, who joined the UFS in 2019, is behind his department using Lutetium 177 PSMA (Lu-177 PSMA) therapy to treatment metastatic castrate resistant prostate cancer (MCRPC) – an advanced stage prostate cancer. 
The UFS and the Free State province can now join other South African universities, like the University of Pretoria, University of the Witwatersrand, and other provinces in using this method to treat MCRPC patients. 

Built for this job

Dr Evbuomwan explains nuclear medicine is a medical specialty that involves the use of unsealed sources of radiation in the form of radioisotopes for the diagnosis and treatment of various disease conditions including cancers.
“It’s novelty and opportunity for research and ability to diagnose and treat disease conditions in one specialty attracted me to this field. I always wanted to be a doctor. I see it as a calling. It was also something my mum discovered while I was growing up as a child. In my next life, I would choose to be a medical doctor again,” he says.

“I was built for this job and it is always my joy to have the opportunity to carry out my work. We have been well-trained for this; we support all our skills with prayers. We try to give our patients the very best,” says Dr Evbuomwan, who is originally from Benin City, Edo state, Nigeria. 

After graduating as a nuclear medicine specialist from Wits University, Dr Evbuomwan moved to the City of Roses after a work opportunity opened. He saw it as an opportunity to showcase his talents.

“I have been privileged to receive training in this treatment during my residency training at Wits. I treated a few of these patients during my training and the results were amazing. The University of Pretoria has also been involved with this treatment, with some amazing results that are recognised worldwide. 

“This was enough to convince me to push for our department to also join the powerhouses and offer this treatment to patients who need it. With the influence of a very understanding head of department, Dr Gerrit Engelbrecht, we have been successful in pushing for the commencement of this treatment at our facility,” says Dr Evbuomwan.

Important treatment
According to him, the availability and expertise of Lutetium 177 PSMA (Lu-177 PSMA) therapy to treat MCRPC is very important for the Free State and the UFS, as it is able to offer an option for patients who do not qualify for available conventional treatment and/or who have failed the first line of conventional treatment. 

“In the majority of patients this treatment offers improved quality of life, disease-free progression and improved overall survival. It also alleviates the constant bone pains these patients have to go through daily. To be able to offer this treatment puts the university and the province on the map alongside other top institutions in and outside the country. It also offers opportunity for research,” says Dr Evbuomwan.

He believes with a PET/CT camera for proper staging of these patients with cancer the UFS would be able to expand the treatment of patients suffering from this deadly illness. Currently the university does not possess such a camera and has to use lesser methods in identifying the right patients for this therapy.

News Archive

Digital Storytelling empowers and liberates students
2014-10-17

In January 2014, Jode Brexa, an American Fulbright scholar, came to our university and moved into the guest room at Welwitschia residence.

It so happened that Brexa and Elize Rall, residence head of Welwitschia – better known as Wel-Wel – started talking about digital storytelling. Brexa’s Digital Storytelling project captured Rall’s imagination. Shortly thereafter, Brexa convinced the RC members of Wel-Wel to participate in the project.

Digital storytelling is, on the most basic level, the use of computer-based resources to tell stories. The idea is to combine the art of storytelling with multimedia – including graphics, photos, text, audio, image and/or music.

The Wel-Wel students were taught storytelling skills and each student’s unique story was recorded and edited. It was so successful that they then showed their stories to the Rector and Dean of Students. Brexa will now – with their permission – take their stories to America with her, where she will share it with her community.

During the weekend of 10–12 October 2014, the RC of Wel-Wel introduced 12 learners, who are currently in Grade 10 at the Christiaan Liphoko School, to the project. The learners stayed in the gazellie for the weekend and, in the course of a few days, learned how much power is locked up in their personal stories. They learned that everyone’s story has the power to inspire and empower.

Wel-Wel has been involved in various outreach projects to the community. However, this was the first time that Wel-Wel literally brought the community to their doorstep. This is also not a charitable project. It is uplifted students reaching out to the youth to empower them in order to empower others in turn.

Meanwhile, Brexa also linked the project to the university’s Schools Partnership Project. The programme works through mentorship programmes to uplift previously disadvantaged schools. Hands were also taken with Columba Leadership NGO – financed by Old Mutual.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept